title: Increased level of von Willebrand factor is significantly and independently associated with diabetes in postinfarction patients. THROMBO Investigators.
abstract: Diabetes is an established risk factor for reinfarction and cardiac death in postinfarction patients. Since the underlying mechanism of diabetes-related risk is not fully understood we aimed to evaluate the association between lipids, thrombogenic factors and diabetes in postinfarction patients. The study population consisted of 1,045 postinfarction patients (846 non-diabetic, 125 non-insulin- and 74 insulin-requiring diabetics) with the following blood tests performed 2 months after an index myocardial infarction: lipoprotein (a), apolipoprotein-B, apolipoprotein-A, cholesterol, HDL cholesterol, triglycerides, insulin, von Willebrand factor (vWF), fibrinogen, factor VII, D-dimer, and plasminogen activator inhibitor (PAI-1). After adjustment for relevant clinical covariates, non-insulin-requiring diabetes was significantly (p < 0.05) associated with elevated levels of (odd ratios per 1 log unit increase in parenthesis) vWF (1.74) and PAI-1 (1.42) whereas insulin requiring diabetes was associated with even more elevated levels of vWF (4.68), but not with increased levels of PAI-1. No significant differences in lipid levels were observed among three groups. In conclusion, increased level of von Willebrand factor is significantly and independently associated with diabetes in postinfarction patients, suggesting that endothelial damage is the primary mechanisms contributing to an increased occurrence of vascular and cardiac events in diabetic postinfarction patients.
authors.affiliation: Department of Medicine, University of Rochester Medical Center, NY 14642, USA. heartwz@heart.rochester.edu
authors.forename: W
authors.initials: W
authors.lastname: Zareba
authors.forename: G
authors.initials: G
authors.lastname: Pancio
authors.forename: A J
authors.initials: AJ
authors.lastname: Moss
authors.forename: V G
authors.initials: VG
authors.lastname: Kalaria
authors.forename: V J
authors.initials: VJ
authors.lastname: Marder
authors.forename: H J
authors.initials: HJ
authors.lastname: Weiss
authors.forename: L F
authors.initials: LF
authors.lastname: Watelet
authors.forename: C E
authors.initials: CE
authors.lastname: Sparks
mesh_terms: D000328:Adult; D000368:Aged; D001786:Blood Glucose / Q000032:analysis; D001798:Blood Proteins / Q000032:analysis; D003289:Convalescence; D003920:Diabetes Mellitus / Q000097:blood*; D003922:Diabetes Mellitus, Type 1 / Q000097:blood; D003924:Diabetes Mellitus, Type 2 / Q000097:blood; D004730:Endothelium, Vascular / Q000473:pathology; D005260:Female; D006801:Humans; D007328:Insulin / Q000097:blood; D008055:Lipids / Q000097:blood; D008074:Lipoproteins / Q000097:blood; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D009203:Myocardial Infarction / Q000097:blood*; D009518:New York / Q000453:epidemiology; D016017:Odds Ratio; D017395:Plasminogen Activator Inhibitor 1 / Q000032:analysis; D012307:Risk Factors; D014841:von Willebrand Factor / Q000032:analysis*
chemical_list: D001786:Blood Glucose; D001798:Blood Proteins; D007328:Insulin; D008055:Lipids; D008074:Lipoproteins; D017395:Plasminogen Activator Inhibitor 1; D014841:von Willebrand Factor